Multiple Sclerosis Treatment Becomes Canada’s First MS Stem Cell Clinical Trial.

The University of Ottawa trial infuses MSCs to reduce inflammation in the central nervous systems of MS patients.

The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients. Continue reading

Multiple Sclerosis Trial Exhibits Positive Results of Stem Cell Therapy.

A five year phase II clinical trial has shown initial success in treating multiple sclerosis.

In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations.  The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading

Multiple Sclerosis Therapy Incorporates Stem Cells in Clinical Trial

Mesenchymal Stem Cell Therapy has been deemed safe for patients suffering from multiple sclerosis.

A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans.  27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection. Continue reading

Multiple Sclerosis Therapy Incorporates Stem Cells in Clinical Trial

Mesenchymal Stem Cell Therapy has been deemed safe for patients suffering from multiple sclerosis.

A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans.  27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection. Continue reading